Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.55 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20460467 | 0.89 | NPC1 (0.60) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL31365964 | 0.88 | L3MBTL1 (0.60) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL4395941 | 0.87 | L3MBTL1 (0.63) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL8288231 | 0.84 | RAB9A (0.65) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL20641182 | 0.84 | RAB9A (0.65) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL1134961 | 0.84 | LMNA (0.59) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL3407375 | 0.83 | SMN1; SMN2 (0.60) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL3529853 | 0.83 | RAB9A (0.60) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL4043558 | 0.83 | RAB9A (0.60) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL11263672 | 0.83 | LMNA (0.60) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575204-B2 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| EP-1654235-B1 | 3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2258687-B1 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8252818-B2 | Nicotinamide derivatives useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2258687-A1 | Nicotinamide derivates useful as P38 inhibitors | Glaxosmithkline LLC (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7838540-B2 | 3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20100215652-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | ASTON NICOLA MARY | 2010-08-26 | — | — | US | disclosed |
| US-20100215661-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-08-26 | — | — | US | disclosed |
| US-7709506-B2 | Nicotinamide derivatives useful as p38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1864975-A2 | Novel compounds | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1474395-B1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20070161684-A1 | 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors | SIMITHKLINE BEECHMAN CORPORATION (US) | 2007-07-12 | — | — | US | disclosed |
| US-20060276516-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20060264479-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-11-23 | — | — | US | disclosed |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | GLAXOSMITHKLINE LLC | 2005-08-11 | — | — | US | disclosed |
| EP-1242396-A1 | NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044213-A1 | NEW P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
| EP-0918770-A1 | PYRIDYL-PIPERAZINYL-PHENYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | AstraZeneca AB (SE) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998001447-A1 | PYRIDYL-PIPERAZINYL-PHENYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ZENECA LIMITED (GB) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161684-A1 | 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors | MAPK1, MAPK3, MAPKAPK2 | RAB9A 1054/4885SMN1; SMN2 2258/4885NPC1 1386/4885 |
| US-20060264479-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | MAPK1, MAPK7, MAPK6 | RAB9A 1389/4885SMN1; SMN2 1259/4885NPC1 1358/4885 |
| US-20100215661-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | MAPK1, MAPK7, MAPK4 | RAB9A 1582/4885SMN1; SMN2 1380/4885NPC1 1409/4885 |
| US-20060276516-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | MAPK1, MAPK7, MAPK6 | RAB9A 1389/4885SMN1; SMN2 1259/4885NPC1 1358/4885 |
| US-20100215652-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | MAPK1, MAPK7, MAPK4 | RAB9A 1582/4885SMN1; SMN2 1380/4885NPC1 1409/4885 |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | MAPK1, MAPK7, MAPK6 | RAB9A 1389/4885SMN1; SMN2 1259/4885NPC1 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.